Bicara Therapeutics (BCAX) COO exercises stock options and sells shares

Q: What insider transaction did Bicara Therapeutics (BCAX) disclose?

The company disclosed that its President and COO , who is also a director, exercised stock options for 8,000 shares of common stock at $3.7898 per share on December 15, 2025 and sold 8,000 and 4,500 shares of common stock at a weighted average price of $18.6838 per share.

Q: How many Bicara Therapeutics (BCAX) shares does the insider own after the transactions?

Following the reported trades, the insider directly owned 189,141 shares of Bicara Therapeutics common stock and held 141,334 stock options.

Q: At what prices were the Bicara Therapeutics (BCAX) shares bought and sold?

The stock option was exercised at an exercise price of $3.7898 per share. The common shares were sold at a weighted average price of $18.6838 per share, with individual sale prices ranging from $18.55 to $18.88 , inclusive.

Q: What are the key terms of the Bicara Therapeutics (BCAX) stock option involved?

The derivative security is a stock option (right to buy) with an exercise price of $3.7898 per share, expiring on August 8, 2033 . The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023 , subject to the insider’s continued service on each vesting date.

Q: What do the transaction codes M and S mean in the Bicara Therapeutics (BCAX) insider filing?

In the report, code M indicates the exercise of a stock option , while code S indicates an open-market sale of common stock by the insider.

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Bicara Therapeutics reported insider transactions by its President and COO, who is also a director. On December 15, 2025, the insider exercised stock options for 8,000 shares of common stock at an exercise price of $3.7898 per share and, in separate trades, sold 8,000 and 4,500 shares of common stock at a weighted average price of $18.6838 per share under a Rule 10b5-1 trading plan adopted on February 12, 2025.

After these transactions, the insider directly owned 189,141 shares of Bicara common stock and held 141,334 stock options. The option covers 8,000 underlying shares in this transaction, carries a $3.7898 exercise price, expires on August 8, 2033, and vests in sixteen equal quarterly installments following August 8, 2023, subject to continued service.

Insider Trade Summary

Net Seller: 12,500 shares ($233,548)

Net Sell 4 txns

Insider Cohlhepp Ryan

Role President and COO

Sold 12,500 shs ($234K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	8,000	$0.00	--
Exercise	Common Stock	8,000	$3.7898	$30K
Sale	Common Stock	8,000	$18.6838	$149K
Sale	Common Stock	4,500	$18.6838	$84K

Holdings After Transaction: Stock Option (Right to Buy) — 141,334 shares (Direct); Common Stock — 201,641 shares (Direct)

Footnotes (1)

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.55 to $18.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

12/16/2025 - 04:52 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohlhepp Ryan

(Last)

(First)

(Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON

02116

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/15/2025		M⁽¹⁾		8,000	A	$3.7898	201,641	D
Common Stock	12/15/2025		S⁽¹⁾		8,000	D	$18.6838⁽²⁾	193,641	D
Common Stock	12/15/2025		S⁽¹⁾		4,500	D	$18.6838⁽²⁾	189,141	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$3.7898	12/15/2025		M⁽¹⁾			8,000	⁽³⁾	08/08/2033	Common Stock	8,000	$0	141,334	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.55 to $18.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

	/s/ Lara Meisner, Attorney-in-Fact	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Bicara Therapeutics (BCAX) disclose?

The company disclosed that its President and COO, who is also a director, exercised stock options for 8,000 shares of common stock at $3.7898 per share on December 15, 2025 and sold 8,000 and 4,500 shares of common stock at a weighted average price of $18.6838 per share.

How many Bicara Therapeutics (BCAX) shares does the insider own after the transactions?

Following the reported trades, the insider directly owned 189,141 shares of Bicara Therapeutics common stock and held 141,334 stock options.

At what prices were the Bicara Therapeutics (BCAX) shares bought and sold?

The stock option was exercised at an exercise price of $3.7898 per share. The common shares were sold at a weighted average price of $18.6838 per share, with individual sale prices ranging from $18.55 to $18.88, inclusive.

Was the Bicara Therapeutics (BCAX) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states that the sale transactions were executed pursuant to a Rule 10b5-1 trading plan that was adopted on February 12, 2025.

What are the key terms of the Bicara Therapeutics (BCAX) stock option involved?

The derivative security is a stock option (right to buy) with an exercise price of $3.7898 per share, expiring on August 8, 2033. The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the insider’s continued service on each vesting date.

What do the transaction codes M and S mean in the Bicara Therapeutics (BCAX) insider filing?

In the report, code M indicates the exercise of a stock option, while code S indicates an open-market sale of common stock by the insider.